ArticleCureus2024
The Effects of Selective Laser Trabeculoplasty in Patients With Angle Recession Glaucoma: A Case Series.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effectiveness of selective laser trabeculoplasty (SLT) in reducing intraocular pressure (IOP) and medication use in treated and untreated eyes of angle recession glaucoma (ARG) patients within a year post procedure.
methodsA retrospective chart review was conducted on nine ARG patients treated with SLT at George Washington University between January 1, 2008, and January 1, 2022. Patients were excluded if they had no ARG diagnosis, did not undergo SLT, lacked follow-up within one year after SLT, or had undergone laser or glaucoma surgery in the treated or untreated eye within 12 months before SLT. Primary outcomes were IOP reduction and SLT success, defined as a ≥20% reduction in IOP without additional IOP-lowering procedures or medications. Follow-up assessments were conducted at six weeks, six months, and 12 months. Statistical analysis included paired t-tests and ANOVA.
resultsA total of nine eyes from nine ARG patients were included, with a mean age of 62.33 years. SLT treatment success was observed in five out of nine (55.5%) treated eyes at various time points. In untreated contralateral eyes, success was noted in three out of nine patients (33.3%). The mean IOP for SLT-treated eyes at baseline, six-week, six-month, and 12-month visits was 20 ± 6.22 mmHg, 17.39 ± 5.11 mmHg (P > 0.05), 18.69 ± 4.99 mmHg (P > 0.05), and 16.83 ± 3.87 mmHg (P > 0.05), respectively. For the same time points, the mean IOP for untreated eyes was 15 ± 3.28 mmHg (P > 0.05), 14 ± 3.20 mmHg (P > 0.05), 14.38 ± 4.24 mmHg (P > 0.05), and 14.83 ± 3.82 mmHg (P > 0.05), respectively. The average number of medications used for the ipsilateral eye at the baseline, six-week, six-month, and 12-month visits was 3.11 ± 1.27, 3.11 ± 1.05, 3.25 ± 1.04, and 3.50 ± 0.55, with no significant changes over time (P > 0.05). Meanwhile, for the contralateral eye, the average medication use at those same points was 1.00 ± 1.32, 1.00 ± 1.32, 1.13 ± 1.36, and 0.67 ± 0.82, also showing no significant changes (P > 0.05).
conclusionSLT was safe and effective in reducing IOP in a subset of treated ARG eyes, with better outcomes observed in those with higher baseline IOP. While individual responses varied, SLT could be considered a viable treatment option for delaying invasive surgery in ARG patients. Larger studies are needed to confirm long-term efficacy and identify predictors of success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.